Latest news with #EditasMedicine
Yahoo
08-07-2025
- Business
- Yahoo
Cathie Wood shells out $13.9 million for one high-stakes biotech stock
Cathie Wood shells out $13.9 million for one high-stakes biotech stock originally appeared on TheStreet. Amid all the noise over tariffs and rate-cut chatter, the smartest move is often to follow investors who've done it before. 💵💰💰💵 Love her or hate her, Cathie Wood is a true maverick who's made a name finding tomorrow's big disruptors long before anyone else. Now, with a fresh swing at a major biotech stock, it says a lot about where she thinks the next big win will come from. Cathie Wood's love affair with biotech stocks has been part of ARK's DNA since day one. Long before CRISPR became a Wall Street buzzword, Wood's team has been busy, scooping up shares in early-stage gene-editing names. Her Genomic Revolution ETF, ARKG, was one of ARK's first thematic funds, which made a splash by loading up on companies like Editas Medicine and Intellia Therapeutics. The idea was clear: Programmable gene-editing tools could effectively flip medicine from symptom treatment to real cures. That early leap paid off 2019 and 2020, ARKG posted massive gains, led by positive trial results and big-name pharma partnerships, while broader markets were stuck in neutral. Wood has been consistent in backing her biotech picks, regardless of bad trial news or cash crunches. For her, the appeal of gene editing has more to do with rewriting what health care looks like. She sees CRISPR and next-gen editing tools as critical tools in curing diseases outright, cutting treatment costs, while giving patients their lives back. Such a strategy comes with its fair share of risk, but Wood spreads that risk across multiple platforms. For those who back game-changing science, her biotech playbook is clear and effective at spotting revolutionary picks that typically stun Mr. Market. Cathie Wood kicked off what's been a choppy week with a classic ARK move, in loading big on a key biotech stock while locking in gains elsewhere. On Monday, ARK Invest scooped up 659,000 shares of Beam Therapeutics () , splitting the buy between Wood's flagship ARK Innovation ETF and the ARK Genomic Revolution ETF. More Tech Stock News: Google's quiet AI win spells trouble for Amazon Nvidia-backed stock sends a quiet shockwave through the AI world Veteran Tesla analyst drops 4-word call That comes to more than $13 million in fresh Beam stock, following a relatively smaller buy earlier this week worth roughly $571,000. Beam Therapeutics stands out in the ARK portfolio for good reason. Its robust base-editing technology promises remarkably more precise and safer gene edits than standard of slicing through both strands of DNA, Beam's method efficiently swaps out tiny pieces one at a time, making it a lot safer and more precise. That competitive edge has major stakes. Beam's pipeline includes programs for monogenic disorders including sickle cell and beta-thalassemia, along with multiple readouts lined up for this year. Beam's cash position is another plus for Wood, with the business funded into 2027, easing dilution fears that typically rattle biotech names. Also, a major Pfizer partnership in cardiovascular disease adds new layers to Beam's commercial push, while landing it even more credibility on the stock market. Hence, for Wood, Beam essentially ticks every box. Its powerful disruptive science, tangible milestones, and huge upside potential suggest a long-term winner. It's exactly the kind of swing-for-the-fences bet ARK is famous for and has made many millionaires in the process. On the flip side, Wood's team lightened up on Roblox () , selling 31,416 shares worth roughly $3.25 million of the popular gaming stock as it rebounded. That follows ARK's moves last week, where it sold 26,877 shares of the gaming giant. As always, biotech isn't for the faint-hearted, but for Cathie Wood, Beam is the moonshot that's in position to rewrite Wood shells out $13.9 million for one high-stakes biotech stock first appeared on TheStreet on Jul 8, 2025 This story was originally reported by TheStreet on Jul 8, 2025, where it first appeared. Sign in to access your portfolio
Yahoo
03-07-2025
- Business
- Yahoo
Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data
Editas Medicine, Inc. (NASDAQ:EDIT) ranks among the best CRISPR stocks to buy. At the European Hematology Association 2025 Congress on June 12, Editas Medicine, Inc. (NASDAQ:EDIT) revealed new in vivo data showing notable progress in gene editing for beta thalassemia and sickle cell disease. According to the study, a single dose of the company's proprietary targeted lipid nanoparticle (tLNP) in non-human primates exceeded the therapeutic threshold by achieving a mean on-target editing level of 58% in the HBG1/2 promoter region of hematopoietic stem cells. Editas' position in the gene editing market is strengthened by the result, enhancing the company's potential to offer a novel treatment for these illnesses with favorable biodistribution and minimal liver targeting. A clinical-stage biotechnology company, Editas Medicine, Inc. (NASDAQ:EDIT) develops gene-editing treatments that use CRISPR technology to modify patients' genomes to treat genetic diseases. Editas distinguishes itself from other major biotech companies that are seeking alternative genomic therapeutics by using an 'in vivo gene editing upregulation strategy.' While we acknowledge the potential of EDIT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
Yahoo
17-06-2025
- Business
- Yahoo
Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
The clinical-stage biotech is developing gene-editing CRISPR technology. Editas has reported encouraging testing results in laboratory animals. Still, the stock remains speculative amid uncertainties and challenges. 10 stocks we like better than Editas Medicine › The biotechnology sector is a thrilling arena for investors, with a history of delivering groundbreaking medical innovations that have led to massive shareholder returns. Editas Medicine (NASDAQ: EDIT) is a promising clinical-stage company that has captured Wall Street's attention at the forefront of the gene-editing revolution with a unique approach to CRISPR technologies. On the other hand, Editas faces a long road ahead before delivering its first Food and Drug Administration (FDA) approved therapy and reaching its goal of transforming into a commercially sustainable biotech. The stock, with a market capitalization of $170 million, has also been extremely volatile, down 62% over the past year despite a sharp 32% rebound in the past month as of this writing. Here's why you should proceed with caution if you're thinking about buying shares of Editas Medicine for your portfolio. Editas Medicine is developing a CRISPR gene editing system to address serious and rare conditions, such as sickle cell disease, beta thalassemia, and inherited eye disorders. Acting like molecular scissors, the CRISPR/Cas9 technology uses proteins to target specific DNA sequences in a person's genetic code, precisely addressing diseases caused by genetic mutations. More than just a treatment, this personalized medicine aims to deliver durable, curative solutions. Compared to larger biotech players pursuing alternative genomic therapies, Editas stands out with its "in vivo gene editing upregulation strategy." Rather than solely removing or replacing defective genes in the more traditional ex vivo approaches, Editas' method edits DNA directly in the body to enhance beneficial gene expression. In vivo gene editing represents a simplified treatment process without the need for cell extraction and harvesting required in ex vivo solutions. This means in vivo could prove more scalable and cost-effective. Early tests have shown encouraging results. Editas successfully edited blood stem cells in monkeys with one dose and increased a key liver protein in mice, which could help treat diseases. The plan is to formally declare two in vivo development candidates from a group of target cell types or tissues under research this year and launch at least one in vivo human clinical trial by the second half of 2026. The opportunity for Editas is to potentially deliver a first-to-market and best-in-class platform with applications for a wide range of genetic diseases. Before getting too excited about Editas Medicine as an investment, it's important to recognize that the company has substantial work ahead and faces significant technical challenges, including confirming a precise in vivo delivery mechanism and addressing off-target DNA risks. Research and development (R&D) partnerships with companies like Bristol Myers Squibb help validate the science and provide credibility to Editas Medicine's endeavors; yet, the in vivo gene editing approach has not been proven in humans. Reaching statistically significant efficacy and safety thresholds is far from certain. Even in a best-case scenario, Editas could still be several years away from a clear timeline for bringing a new therapy to market. Meanwhile, companies like CRISPR Therapeutics, Beam Therapeutics, and Intellia Therapeutics are all exploring in vivo CRISPR technologies, underscoring the highly competitive field. It's unclear whether Editas has an edge. More pressing for investors is reconciling Editas' weak fundamentals. In the first quarter, the company posted a net loss of $76.1 million, which included a $41 million restructuring charge as it abandoned its ex vivo program, pivoting exclusively to the in vivo strategy. This follows $390 million in negative net income between 2023 and 2024. The expectation is for recurring losses in the foreseeable future. With $221 million in cash on the balance sheet, company management believes it has the liquidity to continue development until mid-2027. Nevertheless, additional funding will likely be necessary to advance into late-stage development, including measures dilutive to shareholders. Any setback in the R&D process or regulatory timeline could force a reset of expectations and send the stock price lower. Balancing the pros and cons of investing in Editas Medicine, I believe the stock is simply too speculative to buy with conviction, as the risks outweigh the upside. The prudent approach is to avoid it, instead focusing on companies with higher-quality fundamentals, including steady growth and consistent profitability. Before you buy stock in Editas Medicine, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Editas Medicine wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,821!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $886,880!* Now, it's worth noting Stock Advisor's total average return is 791% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Dan Victor has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Beam Therapeutics, CRISPR Therapeutics, and Intellia Therapeutics. The Motley Fool recommends Editas Medicine. The Motley Fool has a disclosure policy. Editas Medicine Is Great. Here's Why You Shouldn't Buy It. was originally published by The Motley Fool
Business Upturn
12-06-2025
- Business
- Business Upturn
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approach to treating sickle cell disease and beta thalassemia. CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today shared new in vivo data demonstrating therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic stem cells (HSCs) with a single dose of proprietary targeted lipid nanoparticle (tLNP) in non-human primates (NHPs). This clinically validated approach targeting HBG1/2 promoters to upregulate fetal hemoglobin (HbF) is in pre-clinical development as a potential transformative in vivo gene editing medicine for the treatment of sickle cell disease and beta thalassemia. The Company reported these data in a presentation available today and will detail the data in a poster session on Saturday, June 14th 6:30 – 7:30 p.m. CEST (12:30 – 1:30 p.m. EDT) at the European Hematology Association (EHA) 2025 Congress in Milan, Italy. In this study, the Company's proprietary tLNP formulation delivered HBG1/2 promoter editing cargo to HSCs in NHPs. Latest data from this ongoing NHP study showed that at five months a single intravenous administration of Editas' tLNP resulted in mean on-target editing levels in the HBG1/2 promoter region of 58% in HSCs: well exceeding the predicted editing threshold of ≥25% required for therapeutic benefit. In addition to achieving therapeutically relevant editing levels, the biodistribution data in NHPs with Editas' tLNP continue to show significant de-targeting of the liver in contrast to standard LNPs. 'These data from our in vivo HSC program confirm our ability to achieve high efficiency delivery, therapeutically relevant editing levels and favorable biodistribution in NHPs. These data validate the further development of Editas' proprietary HSC-tLNP for editing of the HBG1/2 promoters for the treatment of sickle cell disease and beta thalassemia,' said Linda C. Burkly, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. Editas Medicine's in vivo HSC program targets HBG1/2 promoters to mimic naturally occurring mechanisms of hereditary persistence of fetal hemoglobin (HPFH) and utilizes proprietary AsCas12a to edit with high efficiency and minimize off-target editing. Editing the HBG1/2 promoters with AsCas12a with the investigational medicine reni-cel led to robust increases in HbF and total hemoglobin (Hb) in clinical trials. The presentation details are listed below. Abstracts can be accessed on the EHA website , and the presentation will be posted on the Editas Medicine website during the conference. Poster Presentation Details: Title: Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for β-hemoglobinopathies Date/Time: Saturday, June 14, 2025, 6:30 – 7:30 p.m. CEST/ 12:30 – 1:30 p.m. EDT Location: Allianz MiCo, Milano Convention Centre Session: Poster Session 2 About Editas Medicine As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit . Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
12-06-2025
- Business
- Yahoo
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approach to treating sickle cell disease and beta thalassemia. CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today shared new in vivo data demonstrating therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic stem cells (HSCs) with a single dose of proprietary targeted lipid nanoparticle (tLNP) in non-human primates (NHPs). This clinically validated approach targeting HBG1/2 promoters to upregulate fetal hemoglobin (HbF) is in pre-clinical development as a potential transformative in vivo gene editing medicine for the treatment of sickle cell disease and beta thalassemia. The Company reported these data in a presentation available today and will detail the data in a poster session on Saturday, June 14th 6:30 - 7:30 p.m. CEST (12:30 – 1:30 p.m. EDT) at the European Hematology Association (EHA) 2025 Congress in Milan, Italy. In this study, the Company's proprietary tLNP formulation delivered HBG1/2 promoter editing cargo to HSCs in NHPs. Latest data from this ongoing NHP study showed that at five months a single intravenous administration of Editas' tLNP resulted in mean on-target editing levels in the HBG1/2 promoter region of 58% in HSCs: well exceeding the predicted editing threshold of ≥25% required for therapeutic benefit. In addition to achieving therapeutically relevant editing levels, the biodistribution data in NHPs with Editas' tLNP continue to show significant de-targeting of the liver in contrast to standard LNPs. 'These data from our in vivo HSC program confirm our ability to achieve high efficiency delivery, therapeutically relevant editing levels and favorable biodistribution in NHPs. These data validate the further development of Editas' proprietary HSC-tLNP for editing of the HBG1/2 promoters for the treatment of sickle cell disease and beta thalassemia,' said Linda C. Burkly, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. Editas Medicine's in vivo HSC program targets HBG1/2 promoters to mimic naturally occurring mechanisms of hereditary persistence of fetal hemoglobin (HPFH) and utilizes proprietary AsCas12a to edit with high efficiency and minimize off-target editing. Editing the HBG1/2 promoters with AsCas12a with the investigational medicine reni-cel led to robust increases in HbF and total hemoglobin (Hb) in clinical trials. The presentation details are listed below. Abstracts can be accessed on the EHA website, and the presentation will be posted on the Editas Medicine website during the conference. Poster Presentation Details: Title: Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for β-hemoglobinopathies Date/Time: Saturday, June 14, 2025, 6:30 - 7:30 p.m. CEST/ 12:30 – 1:30 p.m. EDT Location: Allianz MiCo, Milano Convention Centre Session: Poster Session 2 About Editas Medicine As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit CONTACT: Media and Investor Contacts: media@ ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
